CURE bleeding criteria

Jump to navigation Jump to search

Bleeding Microchapters

Home

Patient Information

Overview

Classification

Bleeding Academic Research Consortium
TIMI bleeding criteria
GUSTO bleeding criteria
CURE bleeding criteria
ACUITY HORIZONS bleeding criteria
STEEPLE bleeding criteria
PLATO bleeding criteria
GRACE bleeding criteria

Causes

Treatment

Emergency Bleeding Control

Reversal of Anticoagulation and Antiplatelet in Active Bleed

Perioperative Bleeding

Anemia Management
Coagulation Monitoring
Coagulation Management
Discontinuation, Bridging, and Reversal of Anticoagulation and Antiplatelet Therapy
Antiplatelet Agents
Heparin
Fondaparinux
Vitamin K Antagonists
New Oral Anticoagulants
Comorbidities Involving Hemostatic Derangement
Specific Surgeries
Cardiovascular Surgery
Gynecological Bleeding
Obstetric Bleeding
Orthopedic/Neurosurgery
Visceral/Transplant Surgery
Pediatric Surgery
Congenital Bleeding Disorders
von Willebrand Disease
Platelet Defects
Hemophilia A and B
Factor VII Deficiency
Rare Bleeding Disorders

CURE bleeding criteria On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of CURE bleeding criteria

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on CURE bleeding criteria

CDC on CURE bleeding criteria

CURE bleeding criteria in the news

Blogs on CURE bleeding criteria

Directions to Hospitals Treating Bleeding

Risk calculators and risk factors for CURE bleeding criteria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

CURE Clinical Trials:

The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial

Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events[1]

  • Major Bleeding

Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial hypotension requiring the use of intravenous inotropic agents) Hemoglobin decrease ≥5 g/dL or required ≥4 U of blood Other major bleeding Transfusion of 2–3 U, intraocular

  • Minor

Led to discontinuation of study drug

References

  1. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006). "Adverse impact of bleeding on prognosis in patients with acute coronary syndromes". Circulation. 114 (8): 774–82. doi:10.1161/CIRCULATIONAHA.106.612812. PMID 16908769.

Template:WH Template:WS